--- title: "In \"Major Banks,\" China International Capital Corporation: Beigene's performance last year met expectations, maintaining an \"Outperform Industry\" rating" type: "News" locale: "en" url: "https://longbridge.com/en/news/277868992.md" description: "CICC released a research report stating that Beigene's performance last year met expectations, with revenue of USD 5.343 billion, a year-on-year increase of 40%. Product revenue was USD 5.282 billion, and GAAP net profit was USD 287 million. Although net profit was slightly below expectations, mainly due to one-time equity investment impairment and non-recurring tax impacts in the fourth quarter, the adjusted full-year net profit met expectations. CICC lowered its revenue forecast for 2026 by 2.7%, maintained its profit forecast at USD 610 million, and introduced a profit forecast for 2027 at USD 870 million for the first time, maintaining an \"outperform\" rating with a target price of HKD 250 for H shares" datetime: "2026-03-05T02:31:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277868992.md) - [en](https://longbridge.com/en/news/277868992.md) - [zh-HK](https://longbridge.com/zh-HK/news/277868992.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277868992.md) | [繁體中文](https://longbridge.com/zh-HK/news/277868992.md) # In "Major Banks," China International Capital Corporation: Beigene's performance last year met expectations, maintaining an "Outperform Industry" rating CICC published a research report indicating that Beigene (06160.HK) achieved results last year that were basically in line with the bank's expectations. The company reported last year's revenue of USD 5.343 billion, a year-on-year increase of 40%, with product revenue of USD 5.282 billion, also a year-on-year increase of 40%. The GAAP net profit was USD 287 million. CICC stated that sales revenue met expectations, while net profit was slightly below the bank's expectations, mainly due to one-time equity investment impairment and non-recurring tax issues in the fourth quarter. Excluding these negative impacts, the full-year net profit is expected to meet expectations. Considering the domestic medical insurance price adjustments and the company's cost control, CICC has lowered its revenue forecast for 2026 by 2.7%, but maintained its profit forecast at USD 610 million and introduced a profit forecast for 2027 at USD 870 million for the first time. The rating remains "outperforming the industry," with the target price for H shares maintained at 250 yuan ### Related Stocks - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [BEONE MEDICINES (06160.HK)](https://longbridge.com/en/quote/06160.HK.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [BeOne Medicines (688235.CN)](https://longbridge.com/en/quote/688235.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [BeiGene, Ltd. (BGNE.US)](https://longbridge.com/en/quote/BGNE.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md) ## Related News & Research - [Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%](https://longbridge.com/en/news/278491064.md) - [These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results](https://longbridge.com/en/news/277930677.md) - [03:03 ETSectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging](https://longbridge.com/en/news/277900089.md) - [Antengene Signs Global License Deal With UCB for Autoimmune Drug Candidate](https://longbridge.com/en/news/277705757.md) - [ZAWYA-PRESSR: Mubadala Bio expands access to critical cardiovascular medications](https://longbridge.com/en/news/278515357.md)